Avenzo Therapeutics Presents Positive Preliminary Phase 1 Results for AVZO-1418 in Solid Tumors
Rapid Read

Avenzo Therapeutics Presents Positive Preliminary Phase 1 Results for AVZO-1418 in Solid Tumors

What's Happening? Avenzo Therapeutics, a clinical-stage biotechnology company, announced positive preliminary clinical data from the Phase 1 portion of its AVENTINE-1 study for AVZO-1418. This drug is a potentially best-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC) designed for locally
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.